Home / Business News (page 115)

Business News

European Health Regulators to Review AstraZeneca’s Investigational Gout Drug

The European Medicines Agency (EMA) has accepted AstraZeneca’s marketing authorization application for its investigational gout drug, which the company acquired through its acquisition of Ardea Biosciences. AstraZeneca said that the EMA accepted its application for lesinurad 200mg tablets for the chronic treatment of hyperuricaemia in gout patients. Lesinurad is a …

Read More »

Kite Pharma and Tel Aviv Sourasky Medical Center Expand Agreement for Novel CAR T Cell Therapy Products

Today, Kite Pharma, Inc. announced that it has expanded its immuno-oncology partnership with Tel Aviv Sourasky Medical Center. The US-based biopharmaceutical company expanded its agreement with the Israeli university to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite’s most advanced programs in cancer immunotherapy. …

Read More »

Strides Enters Licensing Deal with Gilead for HIV Drug

Indian generic drugmaker Strides Arcolab recently announced that it has entered a licensing deal to distribute Gilead Sciences’ HIV drug. The company said that it has entered into a licensing agreement with Gilead, under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both …

Read More »

CytRx Climbs as FDA Removes Clinical Hold on Trials Evaluating its Cancer Candidate

Today, CytRx Corporation announced that US health regulators removed a partial clinical hold on its late-stage cancer trials, causing shares to jump ten percent. The company said that the US Food and Drug Administration (FDA) has removed the partial clinical hold on its aldoxorubicin clinical trials, and enrollment and dosing …

Read More »

Roche Expands its Rare Disease Portfolio with Trophos Acquisition

Swiss drugmaker Roche has signed an agreement to acquire privately-held Trophos for up to $545 million. The acquisition will provide Roche with Trophos’ candidate for the rare and debilitating spinal muscular atrophy (SMA). Trophos’ proprietary screening platform generated olesoxime (TRO19622), which is in mid-stage development for SMA. SMA is a …

Read More »

Intrexon and Ziopharm Oncology Enter CAR-T License Deal with MD Anderson

Intrexon Corporation and its oncology partner Ziopharm Oncology have entered an immunotherapy deal with MD Anderson Cancer Center. The companies announced that they have entered into a broad exclusive licensing agreement with the cancer center, including an exclusive sublicensing agreement through MD Anderson for intellectually property developed at the University …

Read More »

Incyte and Agenus Partner for Development of Immuno-Oncology Products

Incyte and Agenus will partner on immuno-oncology targets in a deal worth up to $410 million. The companies announced today that they have entered into a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocycle Display antibody discovery platform. According to terms of the deal, …

Read More »

Gilead Inks Exclusive Deal with CVS Health for Hepatitis C Drugs

Gilead Sciences Inc.’s shares were up more than two percent Monday following news that the company gained exclusive coverage from CVS Health Corp. CVS Health, the nation’s second-largest pharmacy benefit managers (PBM), said that it would make Gilead’s drugs, Harvoni and Sovaldi, the exclusive option for patients on its commercial …

Read More »